Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
Cancer Research and Treatment. 2019;51(1):158-168 
EGFR mutational status in lung adenocarcinoma: Staging implications or continuous evolution?
The Journal of Thoracic and Cardiovascular Surgery. 2017;154(5):1766-1767
P2.14-05 EGFR Mutation Status and Prognostic Impact in Patients with Surgically Resected Lung Adenocarcinoma
Journal of Thoracic Oncology. 2019;14(10):S831
Analysis of EGFR mutation status in blood and CSF in lung adenocarcinoma patients with EGFR mutation and CNS metastasis by ddPCR
Annals of Oncology. 2017;28:x183
Progression patterns of metastatic lung adenocarcinoma patients with EGFR mutation
Clinical Lung Cancer. 2020;
16 EGFR mutational analysis for adenocarcinoma of the lung; outcome by mutation since the introduction of routine molecular testing in one cancer network
Lung Cancer. 2013;79:S6
A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report
Lung Cancer. 2020;
Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
Radiology and Oncology. 2014;48(2):173-183
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases. 2019;82(1):62
Non–Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non–Small-cell Lung Cancer Favor Adenocarcinoma
Clinical Lung Cancer. 2017;18(3):316-323.e1